The estimated Net Worth of Marshall Urist is at least $7.33 Milhão dollars as of 22 February 2023. Dr Urist owns over 23,333 units of Royalty Pharma plc stock worth over $1,296,409 and over the last 4 years he sold RPRX stock worth over $6,029,210.
Dr has made over 7 trades of the Royalty Pharma plc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 23,333 units of RPRX stock worth $870,321 on 22 February 2023.
The largest trade he's ever made was selling 33,134 units of Royalty Pharma plc stock on 4 June 2021 worth over $1,526,815. On average, Dr trades about 13,003 units every 58 days since 2021. As of 22 February 2023 he still owns at least 46,667 units of Royalty Pharma plc stock.
You can see the complete history of Dr Urist stock trades at the bottom of the page.
Dr. Marshall Urist M.D., Ph.D. is the Exec. VP and Co-Head of Research & Investments at Royalty Pharma plc.
Marshall's mailing address filed with the SEC is C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK, NY, 10022.
Over the last 4 years, insiders at Royalty Pharma plc have traded over $863,995,127 worth of Royalty Pharma plc stock and bought 5,330,350 units worth $152,553,456 . The most active insiders traders include David C Hodgson, William E Ford, eCapital Partners Gp, L.L.C..... On average, Royalty Pharma plc executives and independent directors trade stock every 13 days with the average trade being worth of $7,420,205. The most recent stock trade was executed by Rory B Riggs on 2 January 2024, trading 470,000 units of RPRX stock currently worth $13,221,100.
royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi
Royalty Pharma plc executives and other stock owners filed with the SEC include: